Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience

ConclusionWe showed that belzutifan is safe and well-tolerated with strong disease response for CNS hemangioblastoma in adults with VHL, supporting continued use of belzutifan in this patient population. Future studies should assess duration of treatment, effects of cessation after long-term use, and markers of therapeutic response.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research